{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:22:05Z","timestamp":1781284925454,"version":"3.54.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Histone deacetylase inhibitors (HDACis) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective class I HDACi initially approved for patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas (PTCLs). Romidepsin was withdrawn from its PTCL indication following a negative randomized phase 4 study (romidepsin-CHOP [cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone]) that showed no benefit over CHOP alone, further diminishing options for patients. Herein, we describe the development of, to our knowledge, a first-in-class polymer nanoparticle (PNP) of romidepsin using an innovative amphiphilic diblock copolymer\u2013based nanochemistry platform. Nanoromidepsin exhibited superior pharmacologic properties with improved tolerability and safety in murine models of T-cell lymphoma (TCL). The PNP also exhibited superior antitumor efficacy in multiple models, including in vitro TCL cell lines, ex vivo samples from patients with large granular lymphocyte (LGL) leukemia, and murine TCL xenografts. Nanoromidepsin demonstrated greater accumulation in tumors and a statistically significant improvement in overall survival compared with romidepsin in murine xenograft models. These findings justify the clinical development of nanoromidepsin in patients with T-cell malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027997","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T20:59:01Z","timestamp":1756846741000},"page":"2794-2807","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma"],"prefix":"10.1182","volume":"146","author":[{"given":"Ipsita","family":"Pal","sequence":"first","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-3181","authenticated-orcid":false,"given":"Anuradha","family":"Illendula","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Joyner","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Sanil","family":"Manavalan","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess M.","family":"Deddens","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3832-5394","authenticated-orcid":false,"given":"Ariana","family":"Sabzevari","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4790-8588","authenticated-orcid":false,"given":"Deepthi P.","family":"Damera","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Zuberi","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-3951","authenticated-orcid":false,"given":"Todd E.","family":"Fox","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"4Department of Pharmacology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya E.","family":"Dunlap-Brown","sequence":"additional","affiliation":[{"name":"5Molecular Immunologic and Translational Sciences Core, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallesh D.","family":"Jayappa","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Khalife","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"6Department of Pathology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Feith","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"1University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA"},{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"},{"name":"3Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA"},{"name":"7Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025120411215227700_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-8935-8-3","article-title":"Constitutive heterochromatin formation and transcription in mammals","volume":"8","author":"Saksouk","year":"2015","journal-title":"Epigenetics Chromatin"},{"issue":"3","key":"2025120411215227700_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"key":"2025120411215227700_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"issue":"3","key":"2025120411215227700_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025120411215227700_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front Mol Biosci"},{"key":"2025120411215227700_bib6","doi-asserted-by":"crossref","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable polymeric nanoparticles for drug delivery to solid tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front Pharmacol"},{"issue":"17","key":"2025120411215227700_bib7","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2025120411215227700_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"2025120411215227700_bib9","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2025120411215227700_bib10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025120411215227700_bib11","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025120411215227700_bib12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1535-7163.MCT-20-0377","article-title":"Targeting the T-cell lymphoma epigenome induces cell death, cancer testes antigens, immune-modulatory signaling pathways","volume":"20","author":"Scotto","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2025120411215227700_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120411215227700_bib14","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2025120411215227700_bib15","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation","volume":"41","author":"Kamaly","year":"2012","journal-title":"Chem Soc Rev"},{"issue":"1","key":"2025120411215227700_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1039\/C8BM01285G","article-title":"Polymeric micro- and nanoparticles for immune modulation","volume":"7","author":"Ben-Akiva","year":"2018","journal-title":"Biomater Sci"},{"issue":"4","key":"2025120411215227700_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrd4503","article-title":"A holistic approach to targeting disease with polymeric nanoparticles","volume":"14","author":"Cheng","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2025120411215227700_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijbiomac.2022.09.021","article-title":"Improved paclitaxel delivery with PEG-b-PLA\/zein nanoparticles prepared via flash nanoprecipitation","volume":"221","author":"Ye","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"2025120411215227700_bib19","doi-asserted-by":"crossref","first-page":"103172","DOI":"10.1016\/j.jddst.2022.103172","article-title":"Lyophilized tablets of felodipine-loaded polymeric nanocapsules to enhance aqueous solubility: formulation and optimization","volume":"70","author":"Ibrahim","year":"2022","journal-title":"J Drug Deliv Sci Technology"},{"key":"2025120411215227700_bib20","doi-asserted-by":"crossref","first-page":"933856","DOI":"10.3389\/fbioe.2022.933856","article-title":"The targeting imaging and treatment capacity of gelsolin-targeted and paclitaxel-loaded PLGA nanoparticles in vitro and in vivo","volume":"10","author":"Ji","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"2025120411215227700_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1081\/DDC-100102197","article-title":"Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method","volume":"25","author":"Barichello","year":"1999","journal-title":"Drug Dev Ind Pharm"},{"key":"2025120411215227700_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int J Pharmaceutics"},{"issue":"10","key":"2025120411215227700_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41568-022-00496-9","article-title":"Cancer nanomedicine","volume":"22","author":"Bhatia","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"43","key":"2025120411215227700_bib24","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1073\/pnas.1411499111","article-title":"Investigating the optimal size of anticancer nanomedicine","volume":"111","author":"Tang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2025120411215227700_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"2025120411215227700_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/3-540-45734-8_3","volume-title":"Degradable Aliphatic Polyesters","author":"Edlund","year":"2002","edition":"1st ed"},{"issue":"1-2","key":"2025120411215227700_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2006.06.023","article-title":"PLA\/PLGA nanoparticles for sustained release of docetaxel","volume":"325","author":"Musumeci","year":"2006","journal-title":"Int J Pharm"},{"issue":"2","key":"2025120411215227700_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"issue":"23","key":"2025120411215227700_bib29","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"2025120411215227700_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1745-7254.2007.00565.x","article-title":"FG020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo","volume":"28","author":"Deng","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"2025120411215227700_bib31","author":"Istodax","year":"2009"},{"issue":"1-2","key":"2025120411215227700_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijpharm.2014.05.045","article-title":"Heat induced evaporative antisolvent nanoprecipitation (HIEAN) of itraconazole","volume":"471","author":"Mugheirbi","year":"2014","journal-title":"Int J Pharm"},{"issue":"1","key":"2025120411215227700_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejpb.2005.05.009","article-title":"Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation","volume":"62","author":"Keck","year":"2006","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/23\/2794\/2469623\/blood_bld-2024-027997-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/23\/2794\/2469623\/blood_bld-2024-027997-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:22:01Z","timestamp":1764865321000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/23\/2794\/547086\/Nanoromidepsin-a-polymer-nanoparticle-of-the-HDAC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027997","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,4]]},"published":{"date-parts":[[2025,12,4]]}}}